Skip to main content

Table 4 Risk of cardiovascular disease events associated with current, recent, and cumulative exposure to abacavir among persons living with HIV, in the IMS PharMetric Plus claims database from October 1, 2009 through December 31, 2014

From: Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study

Exposurea

Unadjusted Cox Model HR (95% CI; p value)

Adjusted Cox Model HRb (95% CI; p value)

Marginal Structural Model (sIPTW) HRc (95% CI; p value)

Currentd

1.70 (1.41, 2.05; p < 0.001)

1.32 (1.09, 1.60; p = 0.004)

1.43 (1.18, 1.73; p = 0.001)

Recente

1.66 (1.38, 2.00; p = 0.001)

1.28 (1.06, 1.54; p = 0.01)

1.40 (1.16, 1.69; p = 0.001)

Cumulative (per year)

1.24 (1.12, 1.37; p < 0.001)

1.13 (1.02, 1.25; p = 0.02)

1.18 (1.06, 1.31; p = 0.002)

  1. aSeparate models run for each of current, recent, and cumulative exposure to abacavir
  2. bAdjusted for baseline covariates: gender, tobacco use (ever), substances or alcohol abuse (ever), symptomatic HIV disease, serologic evidence of hepatitis B & C infections, history of stroke, history of cancer, prior myocardial infarction, and time-dependent covariates: age, calendar year, body weight, receipt of anti-hyperglycemic agents (sulfonylureas, biguanides, insulin, thiazolidinedione), receipt of medications for heart disease (i.e. aspirin, beta-blocker, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker), and diagnoses of: diabetes mellitus, chronic kidney disease, dyslipidemia, heart failure, cardiac dysrhythmia, atherosclerosis, and hypertension
  3. cIn addition to adjusting for weights generated from the treatment model using the time-fixed and time-dependent covariates in the adjusted Cox model, the marginal models are adjusted for time-fixed/baseline covariates: sex, ever tobacco use, ever alcohol or substance abuse, symptomatic HIV disease, serologic evidence of hepatitis B & C infections, history of stroke, history of cancer, prior myocardial infarction, and baseline values of time-dependent covariates: age, calendar year, receipt of anti-hyperglycemic agents, receipt of medications for heart disease, and diagnoses of: diabetes mellitus, chronic kidney disease, dyslipidemia, heart failure, cardiac dysrhythmia, atherosclerosis, and hypertension
  4. dReferent group is those not currently exposed to abacavir
  5. eReferent group is those not recently exposed to abacavir
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us